Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Donepezil for mild cognitive impairment.

J Birks1, L Flicker

  • 1University of Oxford, Department of Clinical Geratology, Radcliffe Infirmary, Woodstock Road, Oxford, UK OX2 6HE. jacqueline.birks@geratol.ox.ac.uk

The Cochrane Database of Systematic Reviews
|July 21, 2006
PubMed
Summary

Donepezil showed a modest, short-lived cognitive benefit in mild cognitive impairment (MCI) but was linked to more adverse effects. Evidence does not support its use for delaying Alzheimer's disease onset in MCI patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing falls prevention patient education in hospitals - older people's views on barriers and enablers.

BMC nursing·2024
Same author

RETRACTED ARTICLE: Precision Medicine: The Future Management of Geriatric Conditions.

The journal of nutrition, health & aging·2024
Same author

Hearing Impairment and Incident Frailty in Later Life: The Health in Men Study (HIMS).

The journal of nutrition, health & aging·2023
Same author

Screening for and Managing the Person with Frailty in Primary Care: ICFSR Consensus Guidelines.

The journal of nutrition, health & aging·2020
Same author

Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.

The journal of nutrition, health & aging·2019
Same author

HbA1c Is Associated with Frailty in a Group of Aboriginal Australians.

The Journal of frailty & aging·2019

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Mild cognitive impairment (MCI) may precede dementia, particularly Alzheimer's disease (AD).
  • Current diagnostic criteria for MCI are inconsistent, leading to a heterogeneous patient population.
  • Early intervention in AD may delay disease progression.

Purpose of the Study:

  • To evaluate the efficacy of donepezil in individuals with MCI but without a dementia diagnosis.
  • To assess the impact of donepezil on cognitive function and the progression to dementia in MCI patients.

Main Methods:

  • Systematic review of double-blind, randomized controlled trials comparing donepezil with placebo in MCI patients.
  • Searched specialized databases including CENTRAL, MEDLINE, EMBASE, CINAHL, and PsycINFO.

Related Experiment Videos

  • Extracted and analyzed data from included studies to estimate treatment effects and risks.

    • Main Results:

    • One study showed a modest cognitive benefit (ADAS-Cog13) with 10 mg/day donepezil at 24 weeks, but not on other cognitive measures.
    • Donepezil was associated with significantly more adverse events, primarily gastrointestinal, compared to placebo.
    • The second study found no evidence that donepezil delays the onset of AD after one year or three years.

    Conclusions:

    • The observed cognitive benefits of donepezil in MCI are minor and short-lived.
    • Donepezil treatment in MCI is associated with a significant increase in adverse effects.
    • Current evidence does not support the use of donepezil for patients with mild cognitive impairment.